Isotechnika Pharma Inc IPHAF

RE: An Interesting Possible Scenario

[labumba]

My take :  the 0.8 mg group should have an excellent result on anti acute rejection or as good as TAC group ( check the the 3 month intermin result ...i think it was 0 in acute rejection ). The renal toxicity numbers can be better or worse than those of TAC and also the results could be interpreted in differnent readings e.g. GFR or others . But, again , it is because of its wider therapeitic window and excellent PK/DK  response to each patient's reading, voclosporin dose can be scaled up and down for correcting theacute rejection or renal toxicity . I am confident that Voclosporin is a winner in terms of safety.

As said by others , the dosing trial did meet the end points in the last nr. I don't expect anything being drastic in the presentation.